| Market Cap | 238.77Cr 207.56Cr 193.19Cr 177.37Cr 334.96Cr 23TCr 340.15Cr 2.28TCr 893.75Cr 11TCr 896.71Cr 877.01Cr 38TCr | P/E 2026 * |
-7.84x | P/E 2027 * | -6.51x |
|---|---|---|---|---|---|
| Enterprise Value | 238.77Cr 207.56Cr 193.19Cr 177.37Cr 334.96Cr 23TCr 340.15Cr 2.28TCr 893.75Cr 11TCr 896.71Cr 877.01Cr 38TCr | EV / Sales 2026 * |
57.6x | EV / Sales 2027 * | 64.6x |
| Free-Float |
99.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 238.77Cr | |
| +2.35% | +2.74% | +33.41% | +79.20% | 5.65TCr | |
| -0.21% | -7.38% | +25.34% | +63.02% | 5.36TCr | |
| -2.44% | +1.40% | -15.74% | -16.80% | 2.29TCr | |
| -2.85% | -7.78% | -8.09% | +346.36% | 2.14TCr | |
| +2.49% | -0.92% | +20.31% | -12.15% | 2.03TCr | |
| +0.79% | -1.06% | +29.29% | -33.32% | 1.76TCr | |
| +0.58% | -5.88% | +16.30% | +540.37% | 1.47TCr | |
| -5.25% | -4.23% | +46.41% | +169.05% | 1.33TCr | |
| +3.41% | -6.61% | +163.08% | +280.43% | 1.35TCr | |
| Average | -0.18% | -3.79% | +34.48% | +157.35% | 2.6TCr | |
| Weighted average by Cap. | +0.22% | -2.96% | +28.67% | +119.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.14Cr 3.6Cr 3.35Cr 3.08Cr 5.81Cr 395.63Cr 5.9Cr 40Cr 16Cr 196.96Cr 16Cr 15Cr 660.45Cr | 3.7Cr 3.22Cr 2.99Cr 2.75Cr 5.19Cr 353.08Cr 5.27Cr 35Cr 14Cr 175.78Cr 14Cr 14Cr 589.42Cr |
| Net income | -25Cr -22Cr -20Cr -19Cr -35Cr -2.38TCr -35Cr -237.63Cr -93Cr -1.18TCr -94Cr -92Cr -3.97TCr | -35Cr -30Cr -28Cr -26Cr -49Cr -3.35TCr -50Cr -334.56Cr -131.3Cr -1.67TCr -131.74Cr -128.84Cr -5.59TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
